Does UnitedHealthcare cover GLP-1s?
What UnitedHealthcare (UnitedHealth Group) says on its own pages (uhc.com), sorted by topic. Your own plan documents decide what you get.
Read Sep 28, 2026. Each line names the plan type it applies to.
Does it cover GLP-1s for weight loss?
- UHC’s commercial clinical-pharmacy PA list has a program titled “Plans with Weight Loss/Appetite Suppression Medication Coverage” (i.e. for plans that include weight-loss drug coverage); its drug list includes Foundayo.Employer and commercial plans:
Plans with Weight Loss/Appetite Suppression Medication Coverage – phentermine (all brand products including Adipex-P® and Lomaira™), benzphetamine, Contrave® (naltrexone HCl and bupropion HCl, diethylpropion, Foundayo™ (orforglipron), phendimetrazine, orlistat (Xenical®), Qsymia® (phentermine and topiramate extended-release)
uhcprovider.com, Sep 30, 2026 - The same UHC commercial PA-list entry also names Saxenda, Wegovy injection, Wegovy tablet, Wegovy HD and Zepbound, as a Prior Authorization/Notification program for UnitedHealthcare Commercial Plans.Employer and commercial plans:
Saxenda® (liraglutide), Wegovy® (semaglutide) injection, Wegovy® (semaglutide) tablet, Wegovy HD (semaglutide) and Zepbound™ (tirzepatide) - Prior Authorization/Notification - UnitedHealthcare Commercial Plans
uhcprovider.com, Sep 30, 2026 - UHC’s provider notice on the Medicare GLP-1 Bridge (August 11, 2026) says standard Medicare Part D coverage does not typically include GLP-1 medications for weight management.Medicare:
If this direction is not included, the pharmacy may send the claim to the health plan instead and standard Medicare Part D coverage does not typically include GLP-1 medications for weight management.
uhcprovider.com, Sep 30, 2026 - UHC’s AARP Medicare Part D shopping page says Part D plans generally don’t cover drugs prescribed for weight loss.Medicare:
Part D plans generally don't cover drugs prescribed for anorexia, weight loss, weight gain, fertility, erectile dysfunction, cosmetic purposes or hair growth.
aarpmedicareplans.com, Sep 30, 2026 - A note in UHC’s commercial weight-loss criteria (effective 9/1/2026) says Foundayo and Wegovy tablet “may be in Exclude at Launch”.Employer and commercial plans:
*Foundayo and Wegovy tablet may be in Exclude at Launch
uhcprovider.com, Sep 28, 2026
Does it depend on your employer or plan?
- UHC’s employer/broker article on GLP-1 demand says employers may find it hard to decide whether to cover these drugs or exclude them.Employer and commercial plans:
As a result, employers may find it difficult to decide whether they should cover these drugs or exclude them. And those who choose to cover these drugs may have to explain their decision to employees if they later stop covering them for financial or other reasons.
uhc.com, Sep 30, 2026 - Optum Rx (UnitedHealth Group’s PBM, affiliated with UHC) says in its Weight Engage program plans have the option to cover only the most at-risk obesity populations.Employer and commercial plans:
Plans have the option to cover the most at-risk obesity populations only. Guide members to achieve and sustain their weight loss goals with clinical programs designed to support responsible use of GLP-1 drugs.
business.optum.com, Sep 30, 2026 - Optum Rx says Weight Engage limits anti-obesity medications to people who meet the criteria defined by the plan.Employer and commercial plans:
Control utilization so anti-obesity medications are only used by those who meet the criteria defined by the plan.
business.optum.com, Sep 30, 2026 - UHC’s commercial prior authorization program for weight-loss drugs (program 2026 P 1114-22, effective 9/1/2026) is optional: it is for clients or businesses that have elected to cover weight-loss products with prior authorization.Employer and commercial plans:
This is an optional program that is put in place for clients or businesses that have elected to cover weight loss products with Prior Authorization/Notification.
uhcprovider.com, Sep 28, 2026 - UHC says the same program is also designed to meet regulatory requirements for covering weight-loss drugs in California, New Mexico, North Dakota (Essential Health Benefits) and New York.Employer and commercial plans:
It is also designed to meet regulatory requirements for coverage of weight loss medications in California, New Mexico, North Dakota Essential Health Benefits (EHB) and New York.
uhcprovider.com, Sep 28, 2026
Prior authorization criteria
- UHC’s Medicare GLP-1 Bridge notice lists one CMS eligibility route as BMI of 30 or more with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or above.Medicare:
BMI ≥ 30 and a diagnosis of 1 or more of the following: (A) heart failure with preserved ejection fraction, (B) uncontrolled hypertension (defined as SBP > 140 mm Hg or DBP > 90 mm Hg, despite concurrent treatment with 2 antihypertensive medications) or (C) chronic kidney disease stage 3a or above
uhcprovider.com, Sep 30, 2026 - Under the Bridge, once the first fill is approved, later fills need no new prior authorization unless the patient switches to a different covered GLP-1.Medicare:
Once the first fill is approved, subsequent fills do not require a new prior authorization — unless your patient switches to a different covered GLP-1 medication.
uhcprovider.com, Sep 30, 2026 - In UHC’s commercial weight-loss criteria (effective 9/1/2026), one requirement is a BMI of 30 or more (above the 95th percentile for children), or a BMI of 27 or more with a weight-related condition such as dyslipidemia, hypertension, type 2 diabetes or sleep apnea.Employer and commercial plans:
(1) Body Mass Index (BMI) ≥ 30 kg/m2 or for pediatric patients a BMI > 95th percentile -OR- (2) Both of the following: (a) BMI ≥ 27 kg/m2 -AND- (b) Patient has a weight-related comorbidity (e.g., dyslipidemia, hypertension, type 2 diabetes, sleep apnea)
uhcprovider.com, Sep 28, 2026 - UHC also requires the drug to be used alongside lifestyle changes, such as diet or calorie limits, exercise, behavioral support or a community-based program.Employer and commercial plans:
Used as an adjunct to lifestyle modification (e.g., dietary or caloric restriction, exercise, behavioral support, community-based program)
uhcprovider.com, Sep 28, 2026 - Under UHC’s commercial criteria, a first approval lasts 5 months for Wegovy (injection, tablet or HD) and 6 months for Foundayo or Zepbound.Employer and commercial plans:
Wegovy injection or tablet, Wegovy HD: Authorization will be issued for 5 months. Foundayo, Xenical or Zepbound: Authorization will be issued for 6 months.
uhcprovider.com, Sep 28, 2026 - To renew, UHC asks for weight loss of at least 5% of baseline body weight on Wegovy (injection, tablet or HD) and on “all other appetite suppressants”.Employer and commercial plans:
(b) For Wegovy injection or tablet and Wegovy HD weight loss of ≥ 5% of baseline body weight (4) Weight loss of ≥ 5% of baseline body weight for all other appetite suppressants
uhcprovider.com, Sep 28, 2026 - Renewed approvals of Wegovy, Zepbound, Foundayo, Saxenda and the other listed drugs last 12 months.Employer and commercial plans:
Authorization for Contrave, Foundayo, Qsymia, Saxenda, Wegovy injection or tablet, Wegovy HD, Xenical or Zepbound will be issued for 12 months.
uhcprovider.com, Sep 28, 2026 - In the section of UHC’s criteria for North Dakota fully insured small-group and individual plans (Essential Health Benefits), Wegovy injection, Wegovy HD and Zepbound instead require a BMI of 40 or more (for children, over 120% of the 95th percentile).Employer and commercial plans:
(1) Body Mass Index (BMI) ≥ 40 kg/m2 or for pediatric patients a BMI > 120% of 95th percentile
uhcprovider.com, Sep 28, 2026
Sleep apnea (Zepbound)
- UHC’s commercial PA list includes a program for Zepbound limited to obstructive sleep apnea (prior authorization / non-formulary).Employer and commercial plans:
Zepbound® (tirzepatide) – Obstructive Sleep Apnea Only - Prior Authorization/Non-Formulary - UnitedHealthcare Commercial Plans
uhcprovider.com, Sep 30, 2026 - For UnitedHealthcare Community Plan of Massachusetts (notice dated May 28, 2026), the affected drugs stay covered only for Medicare-covered conditions such as type 2 diabetes, cardiovascular disease or obstructive sleep apnea.Medicaid (MA):
These drugs will continue to be covered for Medicare-covered conditions only, like type 2 diabetes, cardiovascular disease or obstructive sleep apnea. Any indication excluded by Medicare, including weight loss and obesity, will not be covered.
uhcprovider.com, Sep 30, 2026
Heart risk (Wegovy)
- UHC’s commercial PA list includes a program for Wegovy injection and tablets limited to cardiovascular risk reduction and MASH.Employer and commercial plans:
Wegovy® (semaglutide) injection, Wegovy® (semaglutide) tablets - Cardiovascular Risk Reduction and MASH Only - Cardiovascular Risk Reduction and MASH Only - Prior Authorization/Non-Formulary - UnitedHealthcare Commercial Plans
uhcprovider.com, Sep 30, 2026 - For UnitedHealthcare Community Plan of Massachusetts (May 28, 2026), the drugs remain covered for Medicare-covered conditions such as cardiovascular disease.Medicaid (MA):
These drugs will continue to be covered for Medicare-covered conditions only, like type 2 diabetes, cardiovascular disease or obstructive sleep apnea. Any indication excluded by Medicare, including weight loss and obesity, will not be covered.
uhcprovider.com, Sep 30, 2026
Type 2 diabetes
- UHC’s commercial PA list includes a prior authorization/notification program for diabetes GLP-1 drugs Mounjaro, Ozempic, Rybelsus, Trulicity and Victoza.Employer and commercial plans:
Diabetes Medications – GLP-1 & Dual GIP/GLP-1 Receptor Agonists - Mounjaro® (tirzepatide), Ozempic® (semaglutide), Rybelsus® (semaglutide), Trulicity® (dulaglutide), Victoza® (liraglutide) - Prior Authorization/Notification - UnitedHealthcare Commercial Plans
uhcprovider.com, Sep 30, 2026 - UHC’s Bridge notice says the Medicare GLP-1 Bridge does not include Ozempic, Rybelsus, Mounjaro or Trulicity.Medicare:
The program does not include other GLP-1 medications — including Ozempic®, Rybelsus®, Mounjaro®, and Trulicity®.
uhcprovider.com, Sep 30, 2026 - For UnitedHealthcare Community Plan of Massachusetts (May 28, 2026), the drugs remain covered for Medicare-covered conditions such as type 2 diabetes.Medicaid (MA):
These drugs will continue to be covered for Medicare-covered conditions only, like type 2 diabetes, cardiovascular disease or obstructive sleep apnea. Any indication excluded by Medicare, including weight loss and obesity, will not be covered.
uhcprovider.com, Sep 30, 2026
Recent changes
- UHC notice dated May 28, 2026: beginning July 1, 2026, to comply with MassHealth, UnitedHealthcare Community Plan of Massachusetts no longer covers prescription drugs used to treat weight loss and obesity, for all its members.Medicaid (MA):
Beginning July 1, 2026, to comply with MassHealth, we’ll no longer cover prescription drugs used for the treatment of weight loss and obesity. This change applies to all UnitedHealthcare Community Plan of Massachusetts members.
uhcprovider.com, Sep 30, 2026 - UHC’s Rhode Island Community Plan pharmacy page says that, under the state’s FY2027 budget, Rhode Island Medicaid will stop covering certain GLP-1s prescribed solely for weight loss beginning October 1, 2026.Medicaid (RI):
Pursuant to the Rhode Island State Fiscal Year 2027 Enacted Budget, beginning October 1, 2026, Rhode Island Medicaid will no longer cover certain GLP-1 receptor agonists when they are prescribed solely for weight loss.
uhcprovider.com, Sep 30, 2026 - UHC notice dated February 13, 2026: effective Feb. 1, 2026, for Georgia State Health Benefit Plan members in UHC HMO or HDHP plans, only 9amHealth providers may prescribe weight-loss medications (not diabetic GLP-1s like Ozempic and Mounjaro).Employer and commercial plans:
For Georgia State Health Benefit Plan (SHBP) members enrolled in a UnitedHealthcare HMO or high-deductible health plan (HDHP) plan, only 9amHealth care providers may prescribe weight loss medications. This doesn’t apply to diabetic GLP-1s, like Ozempic and Mounjaro.
uhcprovider.com, Sep 30, 2026 - UHC’s provider notice (August 11, 2026) says CMS launched the Medicare GLP-1 Bridge on July 1, 2026.Medicare:
As of July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge program. This short-term demonstration program:
uhcprovider.com, Sep 30, 2026 - UHC says the Bridge operates outside the Medicare Part D coverage UnitedHealthcare offers.Medicare:
Operates outside of your patients’ Medicare Part D coverage offered by UnitedHealthcare
uhcprovider.com, Sep 30, 2026 - UHC’s Bridge notice lists Zepbound KwikPen as included, and says the single-dose Zepbound pen and Zepbound vials are not covered.Medicare:
Zepbound® KwikPen® (The single-dose Zepbound pen and Zepbound vials are not covered.)
uhcprovider.com, Sep 30, 2026 - UHC’s change log for its commercial weight-loss program lists 2026 updates: Wegovy tablet added (February), a clarification that the MASH use has no BMI requirement (April), and Foundayo and Wegovy HD added (May).Employer and commercial plans:
2/2026 Updated to add Wegovy tablet and differentiate by indication. 4/2026 Clarified there is no BMI requirement for MASH indication. 5/2026 Added Foundayo and Wegovy HD to criteria.
uhcprovider.com, Sep 28, 2026
How to check your own plan
- UHC’s pharmacy FAQ says members find specific prescription drug coverage by signing in to their member account.Employer and commercial plans:
You can find more information about specific prescription drug coverage by signing in to your member account.
uhc.com, Sep 30, 2026 - UHC’s ACA Marketplace pharmacy page says that if a drug is not covered or has a coverage rule, the member should talk to their provider, who may request prior authorization or an exception.Individual (ACA) plans:
If your medication is not covered or has a coverage rule or limit, talk to your health care provider. They may be able to ask about a prior authorization or exception to get your medication covered or may switch you to a covered medication that can work for your condition.
uhc.com, Sep 30, 2026
What we could not confirm
- More detail, such as exact BMI cutoffs, is in 6 PDF documents from UnitedHealthcare, which we have not opened.
- 1 of its pages blocked automated reading.
Next steps
- Prior authorization and appeal letter templates
- Can you use the maker's savings card with your coverage?
- If it is not covered: the lowest verified cash prices
Other insurers: Aetna, Anthem Blue Cross and Blue Shield, Blue Cross and Blue Shield of Illinois, Blue Shield of California, Cigna, Florida Blue, Highmark, Humana, Independence Blue Cross, Kaiser Permanente, Molina Healthcare, Oscar Health, Premera Blue Cross, Ambetter, Wellcare, TRICARE, FEP Blue (federal employees), BlueCross BlueShield of South Carolina, CareFirst BlueCross BlueShield